HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and...
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology...
BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet SystemHACKENSACK, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Royal Biologics, a company...
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused...
Top-ranking reinforces commitment to service and humanized care as industry standard Best in KLAS 2023 Best in KLAS Patient Experience...
LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb....
TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue...
Latest EHR Integration from Inovalon Offers Healthcare Providers 99% First Pass Claims Acceptance RateBOWIE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE)...
Expects to Commence Phase 2a of CAReS During the First Quarter of 2023SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE)...
WARSAW, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development...
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce...
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast...
LUMANITY EXPANDS MEDICAL AFFAIRS CAPABILITIES Enhanced solutions to deliver effective medical strategies, cross-functional communication plans, and programs to connect with...
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA,...
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in...